Mankind Pharma Acquires Bharat Serums and Vaccines: A Leap in Women's Health and Critical Care Market

Mankind Pharma has completed its acquisition of Bharat Serums and Vaccines Ltd (BSV) for Rs 13,768 crore. The deal positions Mankind as a market leader in women's health and fertility drugs. BSV's strong R&D capabilities are expected to strengthen Mankind's portfolio in critical care and immunoglobulin products.

Mankind Pharma has finalized its acquisition of Bharat Serums and Vaccines Ltd (BSV) in a deal valued at Rs 13,768 crore, marking a significant strategic advancement in the Indian pharmaceutical landscape.

This acquisition not only elevates Mankind Pharma as a market leader in the women's health and fertility drug sectors but also provides access to high entry barrier products within critical care, supported by BSV's established complex R&D technology platforms.

BSV's portfolio, rich in recombinant and niche biologic developments, complements Mankind's offerings, and the synergy is anticipated to result in broader access to specialized treatments for patients both in India and globally.

(With inputs from agencies.)